Tempus AI, Inc. v. Guardant Health Inc.

IPR2025-01434

Tempus AI petitions the PTAB to invalidate Guardant Health’s 10,689,699 patent covering duplex consensus sequencing, arguing obviousness over Kinde and Miner and citing a new claim‑construction that broadens the scope to cellular DNA.

Jurisdiction
US PTAB
Case Number
IPR2025-01434
Decision Date
15 August 2025
Filing Date
15 August 2025

Detailed Summary

In this petition, Tempus AI challenges Guardant Health’s U.S. Patent No. 10,689,699, which claims methods for error‑corrected DNA sequencing using duplex consensus sequencing. Tempus contends that the claims are unpatentable under 35 U.S.C. §103 because the prior‑art references Kinde (2011) and Miner (2004) disclose the same workflow and tagging methods, especially when applied to circulating cellular DNA—a construction now affirmed by the patent owner in a district‑court brief. The petition argues that earlier IPRs were denied without addressing these merits and that discretionary denial under §325(d) is inappropriate, seeking institution of review for all 27 claims.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Tempus AI, Inc. vs Guardant Health Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call